Longitudinal Outcomes in Immune Checkpoint Inhibitor-Associated Uveitis. (PubMed, Ocul Immunol Inflamm) - Oct 8, 2026 - "Most associated agents were pembrolizumab (27 patients, 93.1%), nivolumab (19, 65.5%), and ipilimumab (9, 31.0%). ICI-associated uveitis often involved clinically significant inflammation and reduced vision. When promptly recognized and managed with appropriate therapy and close follow-up, long-term visual acuity was generally stable."
Checkpoint inhibition • Journal • Inflammation • Macular Edema • Ocular Inflammation • Oncology • Ophthalmology • Uveitis
|
|
Alessandro Feo; Ashley F Stein-Merlob; Edmund Tsui; Elizabeth Hutchins; Eric H Yang; Jeffrey Feng; Justin S Yun; Leila Chew; Melissa G Lechner
|